Journal
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
Volume 56, Issue 14, Pages 717-721Publisher
WILEY-BLACKWELL
DOI: 10.1002/jlcr.3109
Keywords
triphenylphosphonium; fluorine-18; mitochondria; imaging; MitoF; PET
Funding
- Medical Research Council (UK) [RG46503]
- Medical Research Council Technology [A853-0125t]
- MRC [MR/K02308X/1, MC_U105663142] Funding Source: UKRI
- Cancer Research UK [16465] Funding Source: researchfish
- Medical Research Council [MR/K02308X/1, G0001354B, G0001354, G1000183B, MC_U105663142] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0512-10090] Funding Source: researchfish
Ask authors/readers for more resources
Changes in the magnitude of the mitochondrial membrane potential occur in a range of important pathologies. To assess changes in membrane potential in patients, we set out to develop an improved mitochondria-targeted positron emission tomography probe comprising a lipophilic triphenylphosphonium cation attached to a fluorine-18 radionuclide via an 11-carbon alkyl chain, which is well-established to effectively transport to and localise within mitochondria. Here, we describe the radiosynthesis of this probe, 11-[F-18]fluoroundecyl-triphenylphosphonium (MitoF), from no-carrier-added [F-18]fluoride and a fully automated synthetic protocol to prepare it in good radiochemical yields (2-3GBq at end-of-synthesis) and radiochemical purity (97-99%). Copyright (c) 2013 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available